S6 E8: Why Skills Matter in AQP and Signatory Roles
Competence is not just about job titles. Rina & Jean discuss why real skills and practical experience remain essential to understanding the INTENT behind the Code to applying JUDGEMENT in complex appr...
9 Maalis 3min
S6 E7: Global Voices, UK Rules: When Senior Leaders Speak to the Media
In this episode, Rina and Jean discuss what happens when senior global leaders speak about medicines in UK national media - and why even well-intentioned interviews can cross into promotion of prescri...
2 Maalis 3min
S6 E6: “The Best” isn’t balanced: Patient Testimony and Three AZ Video Breaches
Patient stories are powerful and that’s exactly why pharma want to use them. In this episode, Rina and Jean analyse three AstraZeneca videos that used patient testimony describing treatment as “the be...
23 Helmi 2min
S6 E5: Social Media, Pharma and the PMCPA: Three Changes You Really Need to Know
In this episode, Rina and Jean dissect the new PMCPA social media guidance and highlight three key changes that add clarity for pharma companies. Essential listening for anyone signing off or posting ...
16 Helmi 3min
S6 E4: What’s in the Package? PMCPA’s New Deal on Package Deals
The PMCPA has published 14 page guidance on Package Deals. We cut through the fluff and tell you what you need to know & why reviewing existing arrangements now matters for compliance and transparency...
9 Helmi 3min
S6 E3: Lavish by Name? Reading Between the Venue Lines
Can a venue name alone imply excess? Rina and Jean unpack a recent case (Case/0440/01/25) where a meeting held at a “beach hotel” was perceived as lavish. They discuss how optics, assumptions, and l...
2 Helmi 6min
S6 E2: Bottleneck to breakthrough: How AI is changing MLR approval
As MLR queues grow, complexity increases & review pain/boredom set in...there's good news for everyone! Rina & Jean are joined by Harry Bliss & Dan Bentley from Siguru to discuss how AI can help appro...
26 Tammi 5min
S6 E1: Pharma Compliance 2026: Complaints, Trends and Wishful Thinking
Rina and Jean look ahead to UK pharma compliance in 2026, including likely complaint hotspots, familiar risk areas and the big question of PMCPA modernisation.
19 Tammi 5min
